ClinicalTrials.gg
RecruitingNCT07580183Updated May 12, 2026

Spatial Scene Recognition Memory in Epilepsy Surgery

An interventional study of Virtual Tour Recognition Memory Task and Intracranial EEG Recording with Research Electrodes (Aim III only) in Focal Epilepsy, Temporal Lobe Epilepsy and Medically Refractory Epilepsy, sponsored by University of California, Davis. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Primary conditionEpilepsy, Temporal LobeRegistry: Epilepsies, PartialReclassifiedWhy we changed it
Registry
Epilepsies, Partial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsy, Temporal Lobe
Why
  1. The study's listed conditions name Epilepsy, Temporal Lobe, a narrower term within Epilepsies, Partial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, Davis · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jul 2024, registered Apr 2026).
  • Started Jul 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
620
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study investigates the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy and temporal lobe lesions. Standard neuropsychological tests are insensitive to important memory deficits experienced by patients, particularly in spatial/scene memory, recollective experience, and familiarity processing. Using a validated virtual tour paradigm, the study examines how familiarity-based recognition and recall of spatial scenes relate to specific brain structures. In Aim I, a large cohort of patients with varied temporal lobe lesions at Emory University undergoes the virtual tour task with voxel-based lesion-symptom mapping to localize necessary brain regions. In Aim II, scalp event-related potentials and eye tracking in healthy participants at UC Davis characterize the temporal dynamics and lateralization of scene recognition. In Aim III, intracranial EEG recordings (including local field potentials and single-unit activity) in epilepsy surgery patients at UC Davis determine the precise network dynamics underlying spatial scene familiarity and recall. The long-term goal is to improve the prediction and prevention of cognitive morbidity from epilepsy surgery by providing a more complete model of spatial recognition memory circuits.

Read the detailed description

Recognition memory can be divided into familiarity (a sense that something has been encountered before) and recollection (identification or elaborative recall). Patients with temporal lobe epilepsy often report subjective memory difficulties that are not captured by conventional neuropsychological tests, which lack assessments of true episodic and scene memory. This study uses a virtual tour paradigm that objectively separates familiarity-based recognition from recall for spatial scenes. The central hypothesis is that spatial scene recognition memory critically involves the convergence of dorsal and ventral visual streams in the inferior parietal lobule and parahippocampal gyrus, with familiarity-based recognition involving neocortical structures and recall involving the parahippocampal gyrus, entorhinal cortices, and hippocampus. The study employs three complementary approaches: (1) lesion-symptom mapping in \~310 surgical patients and 150 controls, (2) scalp ERP and eye-tracking in 80 healthy participants, and (3) intracranial electrophysiology (LFP and single-unit recordings) in \~80 patients undergoing stereoelectroencephalography (SEEG) for clinical seizure localization. Research electrodes (FDA-approved Dixi micro-macro or Behnke-Fried with tetrode components) are placed at clinically determined locations to additionally capture single-neuron activity. This study was classified as a Basic Experimental Studies in Humans (BESH) mechanism; it does not evaluate a health-related clinical outcome but uses clinical populations and FDA-approved research electrodes to study basic neuroscience questions about memory.

02

Conditions studied

  • Focal Epilepsy
  • Temporal Lobe Epilepsy
  • Medically Refractory Epilepsy
  • Memory Disorders
  • Epilepsy Comorbidities
  • Epilepsy Intractable
  • Epilepsy Surgery
  • Epilepsy, Temporal Lobe
  • Memory Deficits
  • Memory Disorder, Spatial
  • Memory Dysfunction
  • Spatial Perception

Keywords

  • spatial memory
  • recognition memory
  • familiarity
  • recollection
  • neural circuits of memory
  • phenomenology of memory
  • scene memory
  • virtual tour
  • epilepsy surgery
  • SEEG
  • stereo-electroencephalography
  • lesion-symptom mapping
  • network-symptom mapping
  • cognitive electrophysiology
  • event-related potentials
  • intracranial EEG
  • iEEG
  • parahippocampal gyrus
  • perirhinal cortex
  • hippocampus
  • tetrodes
  • deja vu
  • neuropsychology
  • consciousness
03

In context

Epilepsy, Temporal Lobe Reclassified

65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.

This study's planned enrollment of 620 is above the median of 30 across 41 interventional studies indexed under Epilepsy, Temporal Lobe.

Browse Epilepsy, Temporal Lobe studies →

Lead sponsor

University of California, Davis is the lead sponsor of 809 studies on the registry; 142 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 43 (64%) have results posted.

Compared within Epilepsy, Temporal Lobe, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsies, Partial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • For Aims I and III: Diagnosis of focal epilepsy or temporal lobe lesion; patients undergoing evaluation for or having undergone epilepsy surgery
  • For Aim II: Healthy adult participants
  • Full-Scale IQ ≥ 70
  • English proficiency sufficient to understand and complete the task
  • For Aim I: Enrolled in or eligible for Emory University epilepsy surgery research registry
  • For Aim III: Undergoing clinically indicated stereoelectroencephalography (SEEG) at UC Davis Medical Center
  • Able to provide (or for Aim I retrospective component, prior consent in Emory registry)

Exclusion criteria

Exclusion Criteria:

  • Full-Scale IQ \< 70
  • Inability to provide
  • For Aim III: Age > 55 years
  • For Aim II: History of neurological or psychiatric disorder (as applicable per study protocol)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    Aim I: Lesion-Symptom Mapping

    Patients with temporal lobe lesions (n≈310) and healthy controls (n≈150) at Emory University. Retrospective cohort with existing surgical lesions plus prospectively enrolled new surgical patients (\~60 over 5 years). Intervention(s): Behavioral: Virtual Tour Recognition Memory Task; Diagnostic: MRI neuroimaging and neuropsychological assessment

    Behavioral: Virtual Tour Recognition Memory Task · Diagnostic Test: MRI Neuroimaging and Neuropsychological Assessment (Aim I)

  • Experimental
    Aim II: Scalp ERP Study

    Healthy participants (n=80) recruited from UC Davis campus community. Intervention: Behavioral: Virtual Tour Recognition Memory Task (still-image version) during Scalp EEG/ERP recording and eye tracking

    Behavioral: Virtual Tour Recognition Memory Task

  • Experimental
    Aim III: Intracranial EEG

    Patients with epilepsy undergoing clinically indicated SEEG (n≈80) at UC Davis Medical Center. Behavioral Intervention: Virtual Tour Recognition Memory Task; Other Intervention: Intracranial EEG recording via clinically placed electrodes, a minority of which have research microelectrodes (FDA-approved Dixi micro-macro or Behnke-Fried Ad-Tech electrodes)

    Behavioral: Virtual Tour Recognition Memory Task · Device: Intracranial EEG Recording with Research Electrodes (Aim III only)

Interventions

  • BehavioralVirtual Tour Recognition Memory Task

    Participants are passively navigated through virtual tour scenes (5-second video clips) during a study phase and are asked to generate descriptive names for each scene. During the test phase, they view novel, spatially similar (same configuration, different objects), or identical scenes and rate familiarity, indicate old/new judgments, report déjà vu sensations, and attempt to recall scene names. The task consists of two study-test blocks. This is a cognitive/behavioral assessment, not a therapeutic intervention.

  • DeviceIntracranial EEG Recording with Research Electrodes (Aim III only)

    Patients undergoing clinically indicated stereoelectroencephalography (SEEG) for seizure localization have electrodes implanted at locations determined solely by clinical need. In a subset of patients, FDA-approved research electrodes (Dixi micro-macro electrodes or Behnke-Fried As-Tech electrodes with tetrode components) substitute standard clinical electrodes at the same clinically determined locations. These electrodes have the same geometry as clinical electrodes and are FDA-approved. The tetrode component enables single-neuron recording for research purposes and adds no additional risk. Electrode placement is not altered by study participation. Local field potentials (LFP) and, where available, single-unit data are recorded during the virtual tour task and resting state.

  • Diagnostic testMRI Neuroimaging and Neuropsychological Assessment (Aim I)

    Pre- and post-surgical structural MRI (T1-weighted, diffusion-weighted imaging, resting-state fMRI) obtained as part of the clinical epilepsy surgery evaluation at Emory University. Extensive neuropsychological battery administered pre- and post-operatively (6 months and 1 year) including Wechsler memory scales, Rey-Osterrieth Complex Figure, confrontation naming, and additional measures.

06

What researchers measure

Primary outcomes

  1. Scene familiarity discrimination accuracy

    Rate of correct familiarity judgments for spatially similar test scenes versus novel scenes (recognition without identification/RWI effect), measured as the proportion of "familiar" responses to configurally matched scenes minus false alarm rate to novel scenes.

    Time frame: From enrollment until the end of eight weeks, during which time testing is scheduled (Aim II), or during the hospitalization for invasive EEG studies (Aim III). Participants in Aim I can undergo repeat testing (six months, one year, etc.)

  2. Scene recall accuracy

    Proportion of test scenes for which participants correctly recall the name or identifying details of the corresponding study scene (verified recall), separately for identical repeat scenes and configurally similar scenes.

    Time frame: From enrollment until the end of eight weeks, during which time testing is scheduled (Aim II), or during the hospitalization for invasive EEG studies (Aim III). Participants in Aim I can undergo repeat testing (six months, one year, etc.)

  3. Lesion-symptom correlation for familiarity and recall (Aim I)

    Voxel-based lesion-symptom mapping (VBLSM) correlating surgical lesion volumes in temporal lobe subregions (temporopolar, perirhinal, entorhinal, parahippocampal, hippocampal) with familiarity and recall behavioral scores.

    Time frame: Testing is scheduled within eight weeks of enrollment for all patients, with repeat testing at six and 12 months after surgery for those enrolled pre-operatively

  4. ERP amplitude and latency associated with familiarity and recall (Aim II)

    Amplitude and latency of event-related potential components (FN400, late positive component) in specified scalp regions (e.g., LAS, RAS, LPS, RPS) as a function of scene familiarity and recall conditions.

    Time frame: During EEG recording session

  5. Intracranial theta and gamma power and connectivity during familiarity judgments (Aim III)

    Theta (3-7 Hz) and gamma-band (30-150 Hz) event-related synchronization/desynchronization in parahippocampal, perirhinal, entorhinal, and hippocampal contacts during familiarity versus recall conditions, plus functional connectivity measures (imaginary coherence, phase-amplitude coupling).

    Time frame: During intracranial EEG monitoring (typically 1-2 weeks hospital stay)

Secondary outcomes

  1. Déjà vu report rate

    Proportion of test trials in which participants report a feeling of déjà vu, analyzed by scene condition (similar, repeat, novel).

    Time frame: During testing sessions with the virtual tour

  2. Vividness of Visual Imagery Questionnaire, Second Edition (VVIQ-2) scores (Aim I)

    Self-reported vividness of visual imagery correlated with lesion location and recognition memory performance. The VVIQ-2 is a 32-item self-report questionnaire in which each item is rated on a scale from 1 (no image at all) to 5 (perfectly clear and vivid). Total scores range from 32 to 160. Higher scores indicate more vivid visual imagery.

    Time frame: During testing session

  3. Hyperfamiliarity commission errors

    Rate of false positive familiarity judgments for novel scenes (false alarms), as a measure of hyperfamiliarity.

    Time frame: During testing session

  4. Neuropsychological test performance (Aim I)

    Standard neuropsychological battery scores (Wechsler Memory Scale, Rey-Osterrieth Complex Figure, confrontation naming, etc.) correlated with virtual tour performance and lesion characteristics.

    Time frame: Pre-surgery and 6 months / 1 year post-surgery

  5. Single-unit firing rate (subset of patients in Aim III)

    Mean firing rate (spikes per second) of individual neurons recorded from parahippocampal and perirhinal cortex during familiarity versus recall conditions, in patients with tetrode/microelectrode recordings.

    Time frame: During intracranial EEG monitoring

  6. Single-unit stimulus selectivity (subset of patients in Aim III)

    Selectivity index (area under the receiver operating characteristic curve) quantifying the discriminability of familiar versus novel scene conditions in individual neurons recorded from parahippocampal and perirhinal cortex, in patients with tetrode/microelectrode recordings.

    Time frame: During intracranial EEG monitoring

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified behavioral data, EEG/ERP data, and intracranial electrophysiology data will be shared via OpenNeuro and Emory Dataverse upon reasonable request. Identifiable data will remain at collection sites.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available by the end of the performance period or upon publication.

Access criteria: De-identified data will be freely available. Requests prior to publication will be by discussion with the PI. A data use agreement may be required for certain datasets.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jun 2030, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 12, 2026
StartActual
Jul 1, 2024
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07580183
Collaborators
Emory University
Responsible party
Nigel P. Pedersen, BSc MBBS (Associate Professor and Vice Chair of Research, Department of Neurology, University of California, Davis) — Principal investigator
First posted
May 12, 2026
Start date
Jul 1, 2024
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
May 12, 2026

Study contacts

Nigel P Pedersen, MD
Contact
nppedersen@health.ucdavis.edu
916-734-3251

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion